These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Adaptive statistical analysis following sample size modification based on interim review of effect size. Hung HM; Cui L; Wang SJ; Lawrence J J Biopharm Stat; 2005; 15(4):693-706. PubMed ID: 16022173 [TBL] [Abstract][Full Text] [Related]
3. [Aspects of sample size determination and power calculation illustrated on examples from rehabilitation research]. Kutschmann M; Bender R; Grouven U; Berg G Rehabilitation (Stuttg); 2006 Dec; 45(6):377-84. PubMed ID: 17123220 [TBL] [Abstract][Full Text] [Related]
4. Variance estimation in clinical studies with interim sample size re-estimation. Miller F Biometrics; 2005 Jun; 61(2):355-61. PubMed ID: 16011681 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval. Liu GF; Zhu GR; Cui L Stat Med; 2008 Feb; 27(4):584-96. PubMed ID: 17634972 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the statistical power for multiple tests: a case study. Yeo A; Qu Y Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588 [TBL] [Abstract][Full Text] [Related]
7. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F; Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053 [No Abstract] [Full Text] [Related]
8. Minimize the use of minimization with unequal allocation. Proschan M; Brittain E; Kammerman L Biometrics; 2011 Sep; 67(3):1135-41. PubMed ID: 21281276 [TBL] [Abstract][Full Text] [Related]
9. Sample size calculation for the Power Model for dose proportionality studies. Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313 [TBL] [Abstract][Full Text] [Related]
10. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences. Schäfer H; Müller HH Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350 [TBL] [Abstract][Full Text] [Related]
12. Studying the prevention of acute kidney injury: lessons from an 18th-century mathematician. Chertow GM; Palevsky PM; Greene T Clin J Am Soc Nephrol; 2006 Sep; 1(5):1124-7. PubMed ID: 17699335 [No Abstract] [Full Text] [Related]
13. Statistical considerations on design and analysis of bridging and multiregional clinical trials. Tsong Y J Biopharm Stat; 2012 Sep; 22(5):1078-80. PubMed ID: 22946952 [No Abstract] [Full Text] [Related]
14. Properties of internal pilots with the univariate approach to repeated measures. Coffey CS; Muller KE Stat Med; 2003 Aug; 22(15):2469-85. PubMed ID: 12872303 [TBL] [Abstract][Full Text] [Related]
15. A nonparametric two-sample comparison for skewed data with unequal variances. Skovlund E J Clin Epidemiol; 2010 Jun; 63(6):594-5. PubMed ID: 20056384 [No Abstract] [Full Text] [Related]
16. Implementing type I & type II error spending for two-sided group sequential designs. Rudser KD; Emerson SS Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592 [TBL] [Abstract][Full Text] [Related]
17. Sample size for two-stage studies with maintenance therapy. Feng W; Wahed AS Stat Med; 2009 Jul; 28(15):2028-41. PubMed ID: 19382105 [TBL] [Abstract][Full Text] [Related]
18. Operating characteristics of sample size re-estimation with futility stopping based on conditional power. Lachin JM Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019 [TBL] [Abstract][Full Text] [Related]